Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, Jiří Mayer, Arpad Illes, Anna Angona, Alexander Kiani, Aude Charbonnier, Theodoros Marinakis, Leif Stenke, Ansgar Weltermann, Seema Shah, Sharon Supekar, Luigi Di Caprio, Michele Baccarani

Blood (2021) 138 (Supplement 1): 635.

https://doi.org/10.1182/blood-2021-145611

Published: 2021

Journal Articles

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Fermin Sanchez-Guijo, MD PhD, Sergio Matarraz, Eleni Plata, Miguel Sagüés, Montserrat Cortes, Irena Preloznik Zupan, Monica Crugnola, MD, Giovanni Caocci, MD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Tobias Gedde-Dahl, Krzysztof Warzocha, Wieslaw W. Jedrzejczak, Slawomira Kyrcz-Krzemien, MD PhD, Alexander Kiani, Sharon Supekar, AnaRita Ferreira, Seema Shah, Juan Luis Steegmann, Michele Baccarani, MD

Blood (2019) 134 (Supplement_1): 4160.

https://doi.org/10.1182/blood-2019-124710

Published: 2019

Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Blood (2019) 134 (Supplement_1): 2924.

https://doi.org/10.1182/blood-2019-128761

Published: 2019

Journal Articles

Analysis of Risk Factors Determining Incidence and Outcome of Infections in Children and Adults after Hematopoietic Cell Transplantation

Blood (2018) 132 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2018-99-113787

Published: 2018

Journal Articles

Allo-HCT from MUD/MRD for Paroxysmal Nocturnal Hemoglobinuria - 12 Years of Experience

Miroslaw Markiewicz, MD, PhD, Prof., Malwina Rybicka-Ramos, MD, Ph. D., Monika Dzierzak-Mietla, MD, PhD, Anna Koclega, MD, PhD, Krzysztof Bialas, MD, Ewa Mendek-Czajkowska, MD, PhD, Slawomira Kyrcz-Krzemien, Prof

Blood (2016) 128 (22): 5886.

https://doi.org/10.1182/blood.V128.22.5886.5886

Published: 2016

Journal Articles

HLA Class I-Specific Effects in AML with Mutated Nucleophosmin

Kateřina Kuželová, PhD, Christoph Röllig, MD, Zdenek Racil, MD, Juliane S. Stickel, MD, Barbora Brodská, PhD, Johannes Schetelig, MD MSc, Christian Thiede, MD, Gerhard Ehninger, MD, Grzegorz Helbig, MD PhD, Slawomira Kyrcz-Krzemien, Prof, Jiri Mayer, Petr Cetkovsky, MD MBA, PhD

Blood (2016) 128 (22): 5230.

https://doi.org/10.1182/blood.V128.22.5230.5230

Published: 2016

Journal Articles

Final Results from the Phase 3 Traial Areta Comparing a Novel, Extended-Release Anagrelide Formulation to Placebo in Essential Thrombocythemia Patients with Defined Risk Status

Heinz Gisslinger, MD, Christoph Klade, Kudrat Abdulkadyrov, MD, Slawomira Kyrcz-Krzemien, MD PhD, Elena Karyagina, MD, Anait L. Melikyan, MD PhD, Krzysztof Warzocha, Barbara Grohmann-Izay, MD, Juri Hodisch, MD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, Petro E. Petrides, MD PhD, Jiri Schwarz, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 476.

https://doi.org/10.1182/blood.V128.22.476.476

Published: 2016

Journal Articles

An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors

Blood (2016) 128 (22): 628.

https://doi.org/10.1182/blood.V128.22.628.628

Published: 2016

Journal Articles

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3 -ITD + normal karyotype AML patients

Blood (2016) 127 (3): 360–362.

https://doi.org/10.1182/blood-2015-08-662130

Published: 2016

Includes: Supplemental data

Journal Articles

Immune Response in Acute Myeloid Leukemia with Mutated Nucleophosmin

Katerina Kuzelova, PhD, Barbora Brodská, PhD, Jana Marková, Grzegorz Helbig, MD PhD, Slawomira Kyrcz-Krzemien, MD PhD, Petr Cetkovsky, MD MBA, PhD

Blood (2015) 126 (23): 2572.

https://doi.org/10.1182/blood.V126.23.2572.2572

Published: 2015

Journal Articles

No Influence of Post-Transplant Anti-HLA Antibodies on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Mismatched Unrelated Donors

Anna Koclega, MD, PhD, Miroslaw Markiewicz, MD, PhD, Prof., Sylwia Mizia, MSci, Urszula Siekiera, BSci, Alicja Dobrowolska, Monika Dzierzak-Mietla, MD, PhD, Krzysztof Bialas, MD, Slawomira Kyrcz-Krzemien, MD PhD Prof.

Blood (2015) 126 (23): 5538.

https://doi.org/10.1182/blood.V126.23.5538.5538

Published: 2015

Journal Articles

The Importance of the Number of Transplanted Cells with Dipeptidyl Peptidase-4 Expression on the Hematopoietic Recovery and Lymphocyte Reconstitution in Patients with Multiple Myeloma after Autologous Hematopoietic Stem-Cell Transplantation

Anna Kopinska, Malgorzata Krawczyk-Kulis, Joanna Dziaczkowska-Suszek, Katarzyna Bieszczad, Krystyna Jagoda, Slawomira Kyrcz-Krzemien, Prof

Blood (2015) 126 (23): 5415.

https://doi.org/10.1182/blood.V126.23.5415.5415

Published: 2015

Journal Articles

Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study?

Maria Carolina Oliveira, MD PhD, Myriam Labopin, MD, Jörg Henes, MD PhD, John Moore, MD, Nicoletta Del Papa, MD PhD, Ricca Stanciu, Ioanna Sakellari, MD PhD, Roland Schroers, MD, Hans Ulrich Scherer, MD, Slawomira Kyrcz-Krzemien, MD PhD Prof., Thomas Daikeler, MD, Tobias Alexander, Jürgen Finke, MD, Manuela Badoglio, John A Snowden, MD FRCP, FRCPath, Dominique Farge, MD PhD

Blood (2014) 124 (21): 2517.

https://doi.org/10.1182/blood.V124.21.2517.2517

Published: 2014

Journal Articles

Cereblon ( CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium

Blood (2014) 124 (21): 3628.

https://doi.org/10.1182/blood.V124.21.3628.3628

Published: 2014

Journal Articles

Favorable Results of Allo-HSCT from MRD in Patients with Myelofibrosis

Miroslaw Markiewicz, MD PhD, Monika Dzierzak-Mietla, MD PhD, Patrycja Zielinska, MD PhD, Agata Wieczorkiewicz-Kabut, MD PhD, Sylwia Mizia, MSci, Mariusz Matyja, MD, Krzysztof Bialas, MD, Grzegorz Helbig, MD PhD Prof., Anna Koclega, MD PhD, Malwina Rybicka, MD, Lech Sedlak, Tomasz Oleksy, Slawomira Kyrcz-Krzemien, MD PhD Prof.

Blood (2014) 124 (21): 5934.

https://doi.org/10.1182/blood.V124.21.5934.5934

Published: 2014

Journal Articles

Matched and Mismatched Unrelated Donor Versus Unmanipulated Haploidentical Donors for Hematopoietic Cell Transplantation in Acute Leukemia in Remission: A Pair Matched Analysis on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Simona Piemontese, MD, Fabio Ciceri, MD, Myriam Labopin, MD, William Arcese, MD, Slawomira Kyrcz-Krzemien, MD PhD Prof., Stella Santarone, MD, He Huang, MDPhD, Dietrich Beelen, MD, Norbert Claude Gorin, MD PhD, Charles Craddock, MDPhD, Zafer Gulbas, MD, Andrea Bacigalupo, MD, Arnon Nagler, MD, Mohamad Mothy, MD PhD

Blood (2014) 124 (21): 1219.

https://doi.org/10.1182/blood.V124.21.1219.1219

Published: 2014

Journal Articles

Allo-HSCT from MUD/MRD As a Curative Treatment in Paroxysmal Nocturnal Hemoglobinuria

Miroslaw Markiewicz, MD PhD, Anna Koclega, MD PhD, Monika Dzierzak-Mietla, MD PhD, Patrycja Zielinska, MD PhD, Ewa Mendek-Czajkowska, MD PhD, Krzysztof Bialas, MD, Slawomira Kyrcz-Krzemien, MD PhD Prof.

Blood (2014) 124 (21): 1251.

https://doi.org/10.1182/blood.V124.21.1251.1251

Published: 2014

Journal Articles

Association Of Health Care Expenditure With Results Of Allogeneic HSCT For Adults With ALL: An Analysis From Acute Leukemia Working Party Of The EBMT

Sebastian Giebel, MD, Myriam Labopin, MD, Adalberto Ibatici, MD, Paul Browne, MD, Tomasz Czerw, Gérard Socié, MD, PhD, Ali Unal, MD, Slawomira Kyrcz-Krzemien, MD, Andrea Bacigalupo, MD, Hakan Goker, MD, Michael N Potter, MBBS, PhD, Grant McQuaker, MD, Dietrich Beelen, MD, Noel Milpied, MD, PhD, Antonio Campos, MD, Charles Craddock, MD DPhil, Mohamad Mohty, MD, PhD

Blood (2013) 122 (21): 2150.

https://doi.org/10.1182/blood.V122.21.2150.2150

Published: 2013

Journal Articles

CD26+ (dipeptidyl peptidase IV positive) Cells In Harvest Material For Multiple Myeloma Autotransplantation

Anna Kopinska, Malgorzata Krawczyk-Kulis, Joanna Suszek-Dziaczkowska, Katarzyna Bieszczad, Krystyna Jagoda, Slawomira Kyrcz-Krzemien, MD

Blood (2013) 122 (21): 5445.

https://doi.org/10.1182/blood.V122.21.5445.5445

Published: 2013

Journal Articles

The Influence Of Anti-HLA Antibodies On Engraftment and Donor’s Chimerism Following Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Mismatched Unrelated Donors

Miroslaw Markiewicz, MD, PhD, Anna Koclega, MD, PhD, Sylwia Mizia, MSci, Urszula Siekiera, PhD, Alicja Dobrowolska, Monika Dzierzak-Mietla, MD, PhD, Patrycja Zielinska, MD, PhD, Krzysztof Bialas, MD, Slawomira Kyrcz-Krzemien, MD

Blood (2013) 122 (21): 4542.

https://doi.org/10.1182/blood.V122.21.4542.4542

Published: 2013

NARROW

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Analysis of Risk Factors Determining Incidence and Outcome of Infections in Children and Adults after Hematopoietic Cell Transplantation

Allo-HCT from MUD/MRD for Paroxysmal Nocturnal Hemoglobinuria - 12 Years of Experience

HLA Class I-Specific Effects in AML with Mutated Nucleophosmin

Final Results from the Phase 3 Traial Areta Comparing a Novel, Extended-Release Anagrelide Formulation to Placebo in Essential Thrombocythemia Patients with Defined Risk Status

An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3 -ITD + normal karyotype AML patients

Immune Response in Acute Myeloid Leukemia with Mutated Nucleophosmin

No Influence of Post-Transplant Anti-HLA Antibodies on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Mismatched Unrelated Donors

The Importance of the Number of Transplanted Cells with Dipeptidyl Peptidase-4 Expression on the Hematopoietic Recovery and Lymphocyte Reconstitution in Patients with Multiple Myeloma after Autologous Hematopoietic Stem-Cell Transplantation

Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study?

Cereblon ( CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium

Favorable Results of Allo-HSCT from MRD in Patients with Myelofibrosis

Matched and Mismatched Unrelated Donor Versus Unmanipulated Haploidentical Donors for Hematopoietic Cell Transplantation in Acute Leukemia in Remission: A Pair Matched Analysis on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Allo-HSCT from MUD/MRD As a Curative Treatment in Paroxysmal Nocturnal Hemoglobinuria

Association Of Health Care Expenditure With Results Of Allogeneic HSCT For Adults With ALL: An Analysis From Acute Leukemia Working Party Of The EBMT

CD26+ (dipeptidyl peptidase IV positive) Cells In Harvest Material For Multiple Myeloma Autotransplantation

The Influence Of Anti-HLA Antibodies On Engraftment and Donor’s Chimerism Following Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Mismatched Unrelated Donors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only